Phenocopying CHD1 depletion, pharmacological inhibition of IL-6 and dual blockade of PD-1/CTLA-4 showed synergistic effects in preclinical models of PTEN-deficient prostate cancer (27). This evidence concerns the gene CHD1 and prostate carcinoma.